Matches in SemOpenAlex for { <https://semopenalex.org/work/W129035006> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W129035006 endingPage "86" @default.
- W129035006 startingPage "S17" @default.
- W129035006 abstract "To assess the feasibility of administering sequential cycles of dose-intensive therapy, 14 patients without prior chemotherapy for metastatic breast cancer were registered to be treated with paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) at an initial dose of 250 mg/m2 over 24 hours (day 1), followed by carboplatin dosed to an area under the concentration-time curve of 16 (calculated according to the Calvert formula), every 3 weeks for four cycles. This combination was supported with peripheral blood stem cells collected following granulocyte colony-stimulating factor with or without cyclophosphamide and paclitaxel. One patient failed to peripheralize CD34 cells after cyclophosphamide/paclitaxel therapy and was taken off protocol. The remaining 13 patients entered the paclitaxel/carboplatin phase of the program, and nine completed all four cycles. The median duration of severe neutropenia (absolute neutrophil count < 100/microL) was 6 days, despite the absence of routine use of granulocyte colony-stimulating factor. Only five of a total of 42 chemotherapy cycles (12%) were associated with febrile neutropenia requiring hospitalization. Most patients did not require platelet transfusions. The most significant nonhematologic toxicity was gastrointestinal (grade 3 in three patients, two of whom had received local radiation for relapse before chemotherapy). Most patients developed grade 1 or 2 sensory neuropathy by the final cycle. Of the nine patients who entered the paclitaxel/carboplatin phase and were evaluable for response, five achieved a complete remission. This doublet of high-dose therapy can be given in an entirely ambulatory setting and is associated with modest hematologic toxicity. The value of this option in the treatment of metastatic breast cancer compared with more conventional approaches to high-dose therapy will require a greater number of patients evaluable for response and longer follow-up." @default.
- W129035006 created "2016-06-24" @default.
- W129035006 creator A5015464704 @default.
- W129035006 creator A5052307461 @default.
- W129035006 creator A5052894313 @default.
- W129035006 creator A5078749917 @default.
- W129035006 date "1997-10-01" @default.
- W129035006 modified "2023-10-12" @default.
- W129035006 title "A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer." @default.
- W129035006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9374101" @default.
- W129035006 hasPublicationYear "1997" @default.
- W129035006 type Work @default.
- W129035006 sameAs 129035006 @default.
- W129035006 citedByCount "1" @default.
- W129035006 crossrefType "journal-article" @default.
- W129035006 hasAuthorship W129035006A5015464704 @default.
- W129035006 hasAuthorship W129035006A5052307461 @default.
- W129035006 hasAuthorship W129035006A5052894313 @default.
- W129035006 hasAuthorship W129035006A5078749917 @default.
- W129035006 hasConcept C121608353 @default.
- W129035006 hasConcept C126322002 @default.
- W129035006 hasConcept C141071460 @default.
- W129035006 hasConcept C143998085 @default.
- W129035006 hasConcept C2775930923 @default.
- W129035006 hasConcept C2776694085 @default.
- W129035006 hasConcept C2776755627 @default.
- W129035006 hasConcept C2777063308 @default.
- W129035006 hasConcept C2777292972 @default.
- W129035006 hasConcept C2777767877 @default.
- W129035006 hasConcept C2778239845 @default.
- W129035006 hasConcept C2778850193 @default.
- W129035006 hasConcept C2781451048 @default.
- W129035006 hasConcept C530470458 @default.
- W129035006 hasConcept C71924100 @default.
- W129035006 hasConcept C74133956 @default.
- W129035006 hasConcept C90924648 @default.
- W129035006 hasConceptScore W129035006C121608353 @default.
- W129035006 hasConceptScore W129035006C126322002 @default.
- W129035006 hasConceptScore W129035006C141071460 @default.
- W129035006 hasConceptScore W129035006C143998085 @default.
- W129035006 hasConceptScore W129035006C2775930923 @default.
- W129035006 hasConceptScore W129035006C2776694085 @default.
- W129035006 hasConceptScore W129035006C2776755627 @default.
- W129035006 hasConceptScore W129035006C2777063308 @default.
- W129035006 hasConceptScore W129035006C2777292972 @default.
- W129035006 hasConceptScore W129035006C2777767877 @default.
- W129035006 hasConceptScore W129035006C2778239845 @default.
- W129035006 hasConceptScore W129035006C2778850193 @default.
- W129035006 hasConceptScore W129035006C2781451048 @default.
- W129035006 hasConceptScore W129035006C530470458 @default.
- W129035006 hasConceptScore W129035006C71924100 @default.
- W129035006 hasConceptScore W129035006C74133956 @default.
- W129035006 hasConceptScore W129035006C90924648 @default.
- W129035006 hasIssue "5 Suppl 17" @default.
- W129035006 hasLocation W1290350061 @default.
- W129035006 hasOpenAccess W129035006 @default.
- W129035006 hasPrimaryLocation W1290350061 @default.
- W129035006 hasRelatedWork W129035006 @default.
- W129035006 hasRelatedWork W1495136011 @default.
- W129035006 hasRelatedWork W1890813079 @default.
- W129035006 hasRelatedWork W1954545824 @default.
- W129035006 hasRelatedWork W2041841240 @default.
- W129035006 hasRelatedWork W2332362313 @default.
- W129035006 hasRelatedWork W2405898975 @default.
- W129035006 hasRelatedWork W2521216538 @default.
- W129035006 hasRelatedWork W2946370795 @default.
- W129035006 hasRelatedWork W95806289 @default.
- W129035006 hasVolume "24" @default.
- W129035006 isParatext "false" @default.
- W129035006 isRetracted "false" @default.
- W129035006 magId "129035006" @default.
- W129035006 workType "article" @default.